Please login to the form below

Not currently logged in
Email:
Password:

Santarus adds two board members

Alessandro Della Chà and Dr Matthew Strobeck join US biopharma

Santarus has appointed Alessandro Della Chà and Dr Matthew Strobeck to its board of directors.

The appointments mean the US-based biopharma firm, which has products including Glumetza (metformin hydrochloride extended release tablets) and Cycloset (bromocriptine mesylate) tablets, has now increased its number of directors to nine.

“We welcome our new board members and look forward to drawing on their industry, business and corporate expertise as we continue to build Santarus into a premier specialty biopharmaceutical company,” said David Hale, chair of Santarus.

Della Chà has been a senior partner of Italian commercial law firm Studio Legale Edoardo Ricci e Associati, since 1997. He has also been co-managing director of the company since 2003. He currently also serves as a director of Cosmo Pharmaceuticals.

Dr Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management from 2008 to 2011. He currently serves as a member of the board of directors of Metabolix.

11th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics